Immunological Evolution of a Cohort of HIV-2 Infected Patients: Peculiarities of an Underestimated Infection.
AIDS
HIV-1
HIV-2
Italy
cART
Journal
Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
09
2021
accepted:
06
02
2022
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
22
4
2022
Statut:
epublish
Résumé
Human Immunodeficiency Virus type 2 (HIV-2) affects a minority of patients in Italy; nevertheless, the increasing migratory flow from higher prevalence areas led to the spread of this virus into our Country. We evaluate clinical, viro-immunological, and therapeutic characteristics of patients with HIV-2 infection and HIV-1/HIV-2 dual-infection and the early treatment impact on overall survival and incidence of AIDS events. We retrospectively analyzed all HIV-2, and HIV-1/HIV-2 positive patients followed in a large Italian clinic from January 1987 to December 2020. We recorded demographic, viro-immunological, clinical, and therapeutic data. We performed a descriptive analysis followed by a longitudinal analysis to explore the factors associated with the CD4+ lymphocyte trend; lastly, we studied the possible predictors of death and AIDS in our cohort in a multivariable model. 32 subjects were enrolled, 17 (53%) HIV-2 infected and 15 (46.8%) HIV-1/HIV-2 dual-infected; 12 patients were lost to follow up, while 3 died. We found a lack of HIV-2 viremia in 12/32 subjects (37.5%). Most of the patients at baseline had a good viro-immunological profile with HIV-2 RNA <200 copies/ml and CD4+ lymphocyte >200 cell/mcl. We found a CD4+ lymphocyte improvement over time, both in the absolute number ( We found a higher prevalence of HIV-1/2 dual infection than in previous observations. Subjects with HIV-2 infection showed a favorable immunological condition at diagnosis, and the benefits of cART in those who received treatment are undiscussed. Moreover, our data suggest a different disease course based on age at diagnosis, as in HIV-1 infections. We encourage starting cART at diagnosis in HIV-2 patients, regardless of CD4+ lymphocyte, because even in the new cART era, CD4+ lymphocyte decrease remains the strongest predictor of death and AIDS also in this population.
Sections du résumé
Background
UNASSIGNED
Human Immunodeficiency Virus type 2 (HIV-2) affects a minority of patients in Italy; nevertheless, the increasing migratory flow from higher prevalence areas led to the spread of this virus into our Country. We evaluate clinical, viro-immunological, and therapeutic characteristics of patients with HIV-2 infection and HIV-1/HIV-2 dual-infection and the early treatment impact on overall survival and incidence of AIDS events.
Methods
UNASSIGNED
We retrospectively analyzed all HIV-2, and HIV-1/HIV-2 positive patients followed in a large Italian clinic from January 1987 to December 2020. We recorded demographic, viro-immunological, clinical, and therapeutic data. We performed a descriptive analysis followed by a longitudinal analysis to explore the factors associated with the CD4+ lymphocyte trend; lastly, we studied the possible predictors of death and AIDS in our cohort in a multivariable model.
Results
UNASSIGNED
32 subjects were enrolled, 17 (53%) HIV-2 infected and 15 (46.8%) HIV-1/HIV-2 dual-infected; 12 patients were lost to follow up, while 3 died. We found a lack of HIV-2 viremia in 12/32 subjects (37.5%). Most of the patients at baseline had a good viro-immunological profile with HIV-2 RNA <200 copies/ml and CD4+ lymphocyte >200 cell/mcl. We found a CD4+ lymphocyte improvement over time, both in the absolute number (
Conclusion
UNASSIGNED
We found a higher prevalence of HIV-1/2 dual infection than in previous observations. Subjects with HIV-2 infection showed a favorable immunological condition at diagnosis, and the benefits of cART in those who received treatment are undiscussed. Moreover, our data suggest a different disease course based on age at diagnosis, as in HIV-1 infections. We encourage starting cART at diagnosis in HIV-2 patients, regardless of CD4+ lymphocyte, because even in the new cART era, CD4+ lymphocyte decrease remains the strongest predictor of death and AIDS also in this population.
Identifiants
pubmed: 35444775
doi: 10.4084/mjhid.2022.016
pii: mjhid-14-1-e2022016
pmc: PMC8992640
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2022016Déclaration de conflit d'intérêts
Competing interests: The authors declare no conflict of Interest.
Références
AIDS. 2001 Nov 23;15(17):2303-10
pubmed: 11698704
N Engl J Med. 2012 Jul 19;367(3):224-32
pubmed: 22808957
Lancet HIV. 2018 Jul;5(7):e390-e399
pubmed: 30052509
J Virol. 1994 Nov;68(11):7433-47
pubmed: 7933127
MMWR Morb Mortal Wkly Rep. 2011 Jul 29;60(29):985-8
pubmed: 21796096
AIDS. 2013 Jan 2;27(1):135-7
pubmed: 23221427
AIDS. 1991 Jul;5(7):859-63
pubmed: 1892591
AIDS. 2013 Sep 24;27(15):2488-91
pubmed: 23939239
Infect Genet Evol. 2016 Dec;46:233-240
pubmed: 27530215
J Virol. 2005 Oct;79(19):12515-27
pubmed: 16160179
JAMA. 1993 Nov 3;270(17):2083-6
pubmed: 8147962
J Gen Virol. 2002 Jun;83(Pt 6):1253-1265
pubmed: 12029140
J Virol. 2005 Jul;79(14):8979-90
pubmed: 15994792
Nature. 1992 Aug 6;358(6386):495-9
pubmed: 1641038
AIDS. 2012 May 15;26(8):951-7
pubmed: 22382142
AIDS. 2014 Feb 20;28(4):549-58
pubmed: 23921613
AIDS Patient Care STDS. 2008 Jun;22(6):489-94
pubmed: 18582190
AIDS. 2003 Dec 5;17(18):2547-60
pubmed: 14685049